Developer docs
API playgroundTry for free, no card

Search company profiles

Replicate Bioscience

Full company profile

uuid00003pk

Namestring
Replicate Bioscience
Legal namestring
Replicate Bioscience, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) therapeutics and vaccines. Its proprietary srRNA platform uses synthetic vectors that, once inside a cell, direct the cell's own machinery to produce multiple copies of a target mRNA, yielding approximately 1,000-fold greater protein expression than linear mRNA and approximately 100-fold greater than first-generation srRNA, with bioactivity demonstrated at doses as low as 0.1 micrograms. The platform underpins a diversified pipeline: a Phase 1-completed rabies vaccine (RBI-4000) with WHO-threshold protection and 6-month durability data published in Nature Communications and Communications Medicine; wholly owned infectious disease vaccines for RSV/hMPV/PIV (RBI-6000) and Epstein-Barr virus (RBI-5000); precision immuno-oncology programs in ER+ breast cancer (RBI-1000) and EGFR-mutant NSCLC (RBI-3000); and protein-replacement therapeutics including a gout candidate (RBI-8000) and undisclosed cardiometabolic targets (RBI-X000).

The company's business model is partnership-driven rather than commercial: it does not sell approved products and operates as a clinical-stage platform. Revenue and funding are generated through enterprise pharma collaborations, non-dilutive grants, and equity financing. The centerpiece is a multi-year collaboration with Novo Nordisk granting worldwide exclusive cardiometabolic rights to the srRNA platform, with up to ~$550 million in upfront, research, and milestone payments plus tiered royalties. A December 2025 agreement with Instituto Butantan grants exclusive Latin American rights to RBI-4000, with Butantan funding registrational trials. Non-dilutive capital has come from three Gates Foundation grants totaling approximately $10 million for HIV, malaria, and tuberculosis vaccines under humanitarian licensing terms, and $46 million in equity from Apple Tree Partners (Series 1 of $6M in February 2021 and Series A of $40M in September 2021). Manufacturing and delivery are enabled through supporting collaborations with Curia (CDMO) and Precision NanoSystems (LNP and microfluidic formulation). Replicate is headquartered in San Diego, California, employs 11–50 people, and is a portfolio company of Apple Tree Partners.

Short descriptiontext

Replicate Bioscience is a clinical-stage San Diego biotech developing self-replicating RNA (srRNA) vaccines and therapeutics for infectious disease, oncology, and autoimmune indications, monetizing its platform through enterprise pharma partnerships (notably Novo Nordisk), regional commercialization deals (Instituto Butantan), and Gates Foundation grants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
self-replicating RNA, RNA therapeutics, mRNA vaccines, precision immuno-oncology, infectious disease vaccines
Industry5 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
RNA Therapeutics and Vaccines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Research funding and milestone payments
TypeLicensing Royalties
Description

Partnerships with pharmaceutical companies providing upfront payments, research funding, and milestone-based payments for development success. Includes the Novo Nordisk partnership worth up to $550 million in research funding and milestone payments.

firstonline.info
2Royalty arrangements
TypeLicensing Royalties
Description

Tiered royalties on future product sales from commercialization agreements, such as the Instituto Butantan partnership for Latin American rabies vaccine commercialization.

prnewswire.com
3Grant funding
TypeProfessional Services
Description

Non-dilutive funding from the Gates Foundation for global health vaccine development including tuberculosis ($3M), HIV ($3.5M), and malaria ($3.5M) vaccine programs.

aijourn.com
4Series A funding
TypeManaged Services
Description

Venture capital funding ($40M Series A from Apple Tree Partners) to advance multiple srRNA programs into clinical development.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Replicate Bioscience develops and licenses a proprietary next-generation self-replicating RNA (srRNA) technology platform that programs cells to repeatedly produce therapeutic proteins at roughly 1000-fold higher expression than linear mRNA, enabling vaccines and immunotherapies at dramatically lower doses. The company is advancing a clinical-stage pipeline of srRNA vaccines (rabies, RSV/hMPV/PIV, EBV), precision immuno-oncology candidates (ER+ breast cancer, EGFRm+ NSCLC), and protein-replacement therapeutics (gout, cardiometabolic disease) primarily through enterprise partnerships with pharmaceutical and global health organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Therapeutic index >100-fold demonstrated clinically with RBI-4000, compared to 1-10-fold for linear mRNA and first-generation srRNA
+4 more records
Product overview1 text field

Replicate Bioscience is a clinical-stage biotechnology company pioneering a proprietary self-replicating RNA (srRNA) technology platform. The platform enables cells to produce their own therapeutic proteins through self-limited replication, achieving approximately 1000-fold expression gain over linear mRNA and 100-fold gain over standard srRNA. The company is advancing a pipeline of srRNA-based vaccines and immunotherapies spanning infectious disease (RBI-4000 for rabies, RBI-6000 for RSV/hMPV/PIV, RBI-5000 for infectious mononucleosis), precision immuno-oncology (RBI-1000 for ER+ breast cancer, RBI-3000 for EGFRm+ NSCLC), and protein drug replacement therapeutics (RBI-8000 for gout, RBI-X000 for cardiometabolic diseases). The srRNA platform is enhanced by a customizable library of synthetic viral vectors, optimized protein inserts, validated delivery systems, and strategic manufacturing collaborations.

Product and service8 records
1RBI-4000
CategoryVaccine
Description

Clinical-stage self-replicating RNA (srRNA) vaccine candidate for rabies prevention encoding the viral glycoprotein; demonstrated protective immunity at doses as low as 0.1 mcg with WHO threshold for protection achieved at all dose levels in Phase 1, and 100% of participants retaining detectable rabies virus neutralizing antibodies at 6 months.

2RBI-6000
CategoryVaccine
Description

Wholly owned srRNA vaccine candidate targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) with multiple antigens encoded on the srRNA vector.

3RBI-5000
CategoryVaccine
Description

Wholly owned srRNA vaccine candidate for infectious mononucleosis caused by Epstein-Barr virus, targeting multiple antigens via the srRNA platform.

4RBI-8000
CategoryTherapeutic
Description

srRNA therapeutic candidate for chronic refractory gout and expansion on proof of concept, targeting pan-inflammasome inhibition through an IL-1 receptor agonist and IL-18 binding protein mechanism; part of the Novo Nordisk cardiometabolic partnership.

5RBI-X000
CategoryTherapeutic
Description

srRNA therapeutic program for obesity, type 2 diabetes, and other cardiometabolic diseases with an undisclosed mechanism, developed under the multi-year Novo Nordisk collaboration worth up to $550 million in research funding and milestones plus tiered royalties.

6RBI-1000
CategoryPrecision Immunotherapy
Description

First-in-class srRNA precision immunotherapy for ER+ breast cancer targeting endocrine therapy resistance mutations via a synthetic immune lethality mechanism combining standard of care with srRNA-trained immune cells; IND-enabling studies ongoing.

7RBI-3000
CategoryPrecision Immunotherapy
Description

srRNA precision immunotherapy candidate targeting acquired resistance to tyrosine kinase inhibitor standard of care therapy for metastatic EGFRm+ non-small cell lung cancer.

8RBI-2000
CategoryProof-of-Concept Therapeutic
Description

Research-stage srRNA candidate encoding two distinct biotherapeutic proteins on a single vector backbone for therapeutic protein delivery; demonstrated tumor control in a preclinical MC38 murine tumor model as proof of concept for multi-protein srRNA expression.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Third research grant of approximately $3 million to advance srRNA vaccine candidates for tuberculosis. Grant subject to humanitarian licensing terms for global health applications in underserved populations. Builds on previous Gates Foundation grants for HIV and malaria vaccine development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Approximately $7 million in combined funding for development of srRNA vaccines targeting HIV (~$3.5M) and malaria (~$3.5M). Grants subject to humanitarian licensing terms addressing two of the world's most persistent public health burdens.

3Instituto Butantan
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Collaboration to develop and commercialize Replicate's srRNA rabies vaccine RBI-4000 in Latin America. Instituto Butantan will conduct registrational clinical trials in Brazil and Latin America, fund development, and obtain manufacturing rights. Replicate retains rights for development in markets outside Latin America and receives tiered royalties on future sales.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-28
Description

Multi-year research collaboration to develop novel srRNA therapies for obesity, type 2 diabetes, and other cardiometabolic diseases. Novo Nordisk receives exclusive worldwide license to use Replicate's srRNA platform for lead programs. Replicate eligible for up to $550 million in research funding, milestone payments, and tiered royalties on future product sales.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-07-26
Description

Licensing deal to scale up genomic medicines. Precision NanoSystems provides access to proprietary LNP delivery systems and microfluidic formulation platform technology.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-06-13
Description

Strategic collaboration to create a groundbreaking development platform for self-replicating RNA (srRNA). Curia provides contract development and manufacturing services to support Replicate's srRNA platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arcturus develops self-amplifying mRNA (saRNA) therapeutics and vaccines using the LUNAR delivery platform, the closest direct competitor to Replicate's srRNA technology. Both companies target infectious-disease vaccines and rare/liver diseases with self-replicating RNA constructs, and both have advanced clinical assets (Arcturus: CSL-partnered saRNA influenza vaccine approved/filed).

TypeDirect peer
Description

Strand is a programmable self-replicating mRNA company focused on oncology and autoimmune disease, directly comparable to Replicate's PIO (precision immuno-oncology) programs RBI-1000 and RBI-3000. Both companies use srRNA as a multi-gene delivery vehicle for cancer and immune indications, competing for the same partner and investor mindshare.

TypeDirect peer
Description

Sail (formerly Laronde) develops endless RNA (eRNA), a circular, self-replicating RNA platform intended for long-duration protein expression. Although structurally distinct from Replicate's srRNA vectors, Sail targets the same fundamental opportunity — durable, low-dose RNA therapeutics — and competes head-to-head with Replicate in pharma partnering discussions.

TypeBroad incumbent
Description

Moderna is the dominant mRNA vaccines and therapeutics company with multiple approved products (Spikevax) and a broad pipeline spanning infectious disease, oncology, and rare disease. While Replicate's srRNA is differentiated, Moderna is actively advancing self-amplifying mRNA candidates and is the most consequential incumbent competitor in the RNA modality.

TypeBroad incumbent
Description

BioNTech is a leading mRNA therapeutics company with deep expertise in cancer vaccines and infectious-disease vaccines, anchored by the Pfizer-partnered Comirnaty franchise. BioNTech's pipeline scope, manufacturing scale, and immuno-oncology focus make it a broad incumbent against Replicate's PIO programs.

TypeBroad incumbent
Description

CureVac is an early mRNA vaccines and therapeutics company developing optimized mRNA constructs for cancer, prophylactic vaccines, and molecular therapy. Although historically focused on linear mRNA, CureVac has invested in next-generation constructs and competes for the same infectious-disease and oncology partnering opportunities as Replicate.

TypeBroad incumbent
Description

Pfizer is a global pharmaceutical incumbent that has invested heavily in mRNA through its partnership with BioNTech and internal RNA programs. Pfizer's prior acquisition of Replicate's predecessor srRNA assets (via the 2019 Janssen/Synthetic Genomics transaction) makes it a particularly relevant incumbent comparator in cardiometabolic and infectious-disease RNA.

TypeBroad incumbent
Description

Sanofi acquired Translate Bio in 2021 and continues to develop mRNA vaccines and therapeutics internally. Sanofi's large infectious-disease and cardiometabolic franchises make it a relevant incumbent comparator, and a potential future partner or competitor for Replicate's srRNA programs.

TypeEmerging player
Description

Vir is a clinical-stage immunology company developing infectious-disease therapeutics with a particular focus on vaccines and monoclonal antibodies. Vir's infectious-disease focus and large-pharma partnerships make it an emerging competitor in the global-health vaccine space where Replicate is most active.

TypeEmerging player
Description

Tessera is developing RNA-based 'gene writing' therapeutics that, while distinct from srRNA, compete in the broader therapeutic modality landscape for in-vivo production of therapeutic proteins. Tessera's emerging gene-writing platform is an adjacent, enabling comparator relevant to Replicate's protein-replacement programs in cardiometabolic disease and gout.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Replicate Bioscience

RNA Therapeutics and Vaccinesreplicatebioscience.com

Replicate Bioscience is a clinical-stage San Diego biotech developing self-replicating RNA (srRNA) vaccines and therapeutics for infectious disease, oncology, and autoimmune indications, monetizing its platform through enterprise pharma partnerships (notably Novo Nordisk), regional commercialization deals (Instituto Butantan), and Gates Foundation grants.

What Replicate Bioscience does

Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) therapeutics and vaccines. Its proprietary srRNA platform uses synthetic vectors that, once inside a cell, direct the cell's own machinery to produce multiple copies of a target mRNA, yielding approximately 1,000-fold greater protein expression than linear mRNA and approximately 100-fold greater than first-generation srRNA, with bioactivity demonstrated at doses as low as 0.1 micrograms. The platform underpins a diversified pipeline: a Phase 1-completed rabies vaccine (RBI-4000) with WHO-threshold protection and 6-month durability data published in Nature Communications and Communications Medicine; wholly owned infectious disease vaccines for RSV/hMPV/PIV (RBI-6000) and Epstein-Barr virus (RBI-5000); precision immuno-oncology programs in ER+ breast cancer (RBI-1000) and EGFR-mutant NSCLC (RBI-3000); and protein-replacement therapeutics including a gout candidate (RBI-8000) and undisclosed cardiometabolic targets (RBI-X000).

The company's business model is partnership-driven rather than commercial: it does not sell approved products and operates as a clinical-stage platform. Revenue and funding are generated through enterprise pharma collaborations, non-dilutive grants, and equity financing. The centerpiece is a multi-year collaboration with Novo Nordisk granting worldwide exclusive cardiometabolic rights to the srRNA platform, with up to ~$550 million in upfront, research, and milestone payments plus tiered royalties. A December 2025 agreement with Instituto Butantan grants exclusive Latin American rights to RBI-4000, with Butantan funding registrational trials. Non-dilutive capital has come from three Gates Foundation grants totaling approximately $10 million for HIV, malaria, and tuberculosis vaccines under humanitarian licensing terms, and $46 million in equity from Apple Tree Partners (Series 1 of $6M in February 2021 and Series A of $40M in September 2021). Manufacturing and delivery are enabled through supporting collaborations with Curia (CDMO) and Precision NanoSystems (LNP and microfluidic formulation). Replicate is headquartered in San Diego, California, employs 11–50 people, and is a portfolio company of Apple Tree Partners.

Replicate Bioscience firmographics

Firmographics
Name
Replicate Bioscience
Legal name
Replicate Bioscience, Inc.
Website
https://replicatebioscience.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Replicate Bioscience is a clinical-stage San Diego biotech developing self-replicating RNA (srRNA) vaccines and therapeutics for infectious disease, oncology, and autoimmune indications, monetizing its platform through enterprise pharma partnerships (notably Novo Nordisk), regional commercialization deals (Instituto Butantan), and Gates Foundation grants.
Ownership category
akta.pro rank

Replicate Bioscience industry classification

Industry
Product category
RNA Therapeutics and Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Self-replicating RNA
  • RNA therapeutics
  • MRNA vaccines
  • Precision immuno-oncology
  • Infectious disease vaccines

Where Replicate Bioscience is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Replicate Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research funding and milestone payments: Partnerships with pharmaceutical companies providing upfront payments, research funding, and milestone-based payments for development success. Includes the Novo Nordisk partnership worth up to $550 million in research funding and milestone payments.
  2. Royalty arrangements: Tiered royalties on future product sales from commercialization agreements, such as the Instituto Butantan partnership for Latin American rabies vaccine commercialization.
  3. Grant funding: Non-dilutive funding from the Gates Foundation for global health vaccine development including tuberculosis ($3M), HIV ($3.5M), and malaria ($3.5M) vaccine programs.
  4. Series A funding: Venture capital funding ($40M Series A from Apple Tree Partners) to advance multiple srRNA programs into clinical development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Replicate Bioscience product offering

Product offering

Core offering

Replicate Bioscience develops and licenses a proprietary next-generation self-replicating RNA (srRNA) technology platform that programs cells to repeatedly produce therapeutic proteins at roughly 1000-fold higher expression than linear mRNA, enabling vaccines and immunotherapies at dramatically lower doses. The company is advancing a clinical-stage pipeline of srRNA vaccines (rabies, RSV/hMPV/PIV, EBV), precision immuno-oncology candidates (ER+ breast cancer, EGFRm+ NSCLC), and protein-replacement therapeutics (gout, cardiometabolic disease) primarily through enterprise partnerships with pharmaceutical and global health organizations.

Product overview

Replicate Bioscience is a clinical-stage biotechnology company pioneering a proprietary self-replicating RNA (srRNA) technology platform. The platform enables cells to produce their own therapeutic proteins through self-limited replication, achieving approximately 1000-fold expression gain over linear mRNA and 100-fold gain over standard srRNA. The company is advancing a pipeline of srRNA-based vaccines and immunotherapies spanning infectious disease (RBI-4000 for rabies, RBI-6000 for RSV/hMPV/PIV, RBI-5000 for infectious mononucleosis), precision immuno-oncology (RBI-1000 for ER+ breast cancer, RBI-3000 for EGFRm+ NSCLC), and protein drug replacement therapeutics (RBI-8000 for gout, RBI-X000 for cardiometabolic diseases). The srRNA platform is enhanced by a customizable library of synthetic viral vectors, optimized protein inserts, validated delivery systems, and strategic manufacturing collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

  • RBI-4000 Clinical-stage self-replicating RNA (srRNA) vaccine candidate for rabies prevention encoding the viral glycoprotein; demonstrated protective immunity at doses as low as 0.1 mcg with WHO threshold for protection achieved at all dose levels in Phase 1, and 100% of participants retaining detectable rabies virus neutralizing antibodies at 6 months.
  • RBI-6000 Wholly owned srRNA vaccine candidate targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) with multiple antigens encoded on the srRNA vector.
  • RBI-5000 Wholly owned srRNA vaccine candidate for infectious mononucleosis caused by Epstein-Barr virus, targeting multiple antigens via the srRNA platform.
  • RBI-8000 srRNA therapeutic candidate for chronic refractory gout and expansion on proof of concept, targeting pan-inflammasome inhibition through an IL-1 receptor agonist and IL-18 binding protein mechanism; part of the Novo Nordisk cardiometabolic partnership.
  • RBI-X000 srRNA therapeutic program for obesity, type 2 diabetes, and other cardiometabolic diseases with an undisclosed mechanism, developed under the multi-year Novo Nordisk collaboration worth up to $550 million in research funding and milestones plus tiered royalties.
  • RBI-1000 First-in-class srRNA precision immunotherapy for ER+ breast cancer targeting endocrine therapy resistance mutations via a synthetic immune lethality mechanism combining standard of care with srRNA-trained immune cells; IND-enabling studies ongoing.
  • RBI-3000 srRNA precision immunotherapy candidate targeting acquired resistance to tyrosine kinase inhibitor standard of care therapy for metastatic EGFRm+ non-small cell lung cancer.
  • RBI-2000 Research-stage srRNA candidate encoding two distinct biotherapeutic proteins on a single vector backbone for therapeutic protein delivery; demonstrated tumor control in a preclinical MC38 murine tumor model as proof of concept for multi-protein srRNA expression.

Quantifiable outcome

  • Therapeutic index >100-fold demonstrated clinically with RBI-4000, compared to 1-10-fold for linear mRNA and first-generation srRNA
  • +4 more outcomes

Companies that use Replicate Bioscience

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Replicate Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Replicate Bioscience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 19 June 2026Third research grant of approximately $3 million to advance srRNA vaccine candidates for tuberculosis. Grant subject to humanitarian licensing terms for global health applications in underserved populations. Builds on previous Gates Foundation grants for HIV and malaria vaccine development.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 8 January 2026Approximately $7 million in combined funding for development of srRNA vaccines targeting HIV (~$3.5M) and malaria (~$3.5M). Grants subject to humanitarian licensing terms addressing two of the world's most persistent public health burdens.
  • Instituto ButantancoreStrategic or Co-development Partner · 4 December 2025Collaboration to develop and commercialize Replicate's srRNA rabies vaccine RBI-4000 in Latin America. Instituto Butantan will conduct registrational clinical trials in Brazil and Latin America, fund development, and obtain manufacturing rights. Replicate retains rights for development in markets outside Latin America and receives tiered royalties on future sales.
  • Novo NordiskcoreStrategic or Co-development Partner · 28 August 2025Multi-year research collaboration to develop novel srRNA therapies for obesity, type 2 diabetes, and other cardiometabolic diseases. Novo Nordisk receives exclusive worldwide license to use Replicate's srRNA platform for lead programs. Replicate eligible for up to $550 million in research funding, milestone payments, and tiered royalties on future product sales.
  • Precision NanoSystemssupportingTechnology or Integration · 26 July 2022Licensing deal to scale up genomic medicines. Precision NanoSystems provides access to proprietary LNP delivery systems and microfluidic formulation platform technology.
  • CuriasupportingTechnology or Integration · 13 June 2022Strategic collaboration to create a groundbreaking development platform for self-replicating RNA (srRNA). Curia provides contract development and manufacturing services to support Replicate's srRNA platform.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Replicate Bioscience competitors and assessment

Company assessment

Direct peers

  • Arcturus Therapeutics: Arcturus develops self-amplifying mRNA (saRNA) therapeutics and vaccines using the LUNAR delivery platform, the closest direct competitor to Replicate's srRNA technology. Both companies target infectious-disease vaccines and rare/liver diseases with self-replicating RNA constructs, and both have advanced clinical assets (Arcturus: CSL-partnered saRNA influenza vaccine approved/filed).
  • Strand Therapeutics: Strand is a programmable self-replicating mRNA company focused on oncology and autoimmune disease, directly comparable to Replicate's PIO (precision immuno-oncology) programs RBI-1000 and RBI-3000. Both companies use srRNA as a multi-gene delivery vehicle for cancer and immune indications, competing for the same partner and investor mindshare.
  • Sail Biomedicines: Sail (formerly Laronde) develops endless RNA (eRNA), a circular, self-replicating RNA platform intended for long-duration protein expression. Although structurally distinct from Replicate's srRNA vectors, Sail targets the same fundamental opportunity — durable, low-dose RNA therapeutics — and competes head-to-head with Replicate in pharma partnering discussions.

Broad incumbents

  • Moderna: Moderna is the dominant mRNA vaccines and therapeutics company with multiple approved products (Spikevax) and a broad pipeline spanning infectious disease, oncology, and rare disease. While Replicate's srRNA is differentiated, Moderna is actively advancing self-amplifying mRNA candidates and is the most consequential incumbent competitor in the RNA modality.
  • BioNTech: BioNTech is a leading mRNA therapeutics company with deep expertise in cancer vaccines and infectious-disease vaccines, anchored by the Pfizer-partnered Comirnaty franchise. BioNTech's pipeline scope, manufacturing scale, and immuno-oncology focus make it a broad incumbent against Replicate's PIO programs.
  • CureVac: CureVac is an early mRNA vaccines and therapeutics company developing optimized mRNA constructs for cancer, prophylactic vaccines, and molecular therapy. Although historically focused on linear mRNA, CureVac has invested in next-generation constructs and competes for the same infectious-disease and oncology partnering opportunities as Replicate.
  • Pfizer: Pfizer is a global pharmaceutical incumbent that has invested heavily in mRNA through its partnership with BioNTech and internal RNA programs. Pfizer's prior acquisition of Replicate's predecessor srRNA assets (via the 2019 Janssen/Synthetic Genomics transaction) makes it a particularly relevant incumbent comparator in cardiometabolic and infectious-disease RNA.
  • Sanofi (Translate Bio): Sanofi acquired Translate Bio in 2021 and continues to develop mRNA vaccines and therapeutics internally. Sanofi's large infectious-disease and cardiometabolic franchises make it a relevant incumbent comparator, and a potential future partner or competitor for Replicate's srRNA programs.

Emerging players

  • Vir Biotechnology: Vir is a clinical-stage immunology company developing infectious-disease therapeutics with a particular focus on vaccines and monoclonal antibodies. Vir's infectious-disease focus and large-pharma partnerships make it an emerging competitor in the global-health vaccine space where Replicate is most active.
  • Tessera Therapeutics: Tessera is developing RNA-based 'gene writing' therapeutics that, while distinct from srRNA, compete in the broader therapeutic modality landscape for in-vivo production of therapeutic proteins. Tessera's emerging gene-writing platform is an adjacent, enabling comparator relevant to Replicate's protein-replacement programs in cardiometabolic disease and gout.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Replicate Bioscience social profiles

Digital presence

Replicate Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Replicate Bioscience leadership team

Management profile

Number of profiles

Profiles8 records

Replicate Bioscience funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Replicate Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Replicate Bioscience

What does Replicate Bioscience do?

Replicate Bioscience develops and licenses a proprietary next-generation self-replicating RNA (srRNA) technology platform that programs cells to repeatedly produce therapeutic proteins at roughly 1000-fold higher expression than linear mRNA, enabling vaccines and immunotherapies at dramatically lower doses. The company is advancing a clinical-stage pipeline of srRNA vaccines (rabies, RSV/hMPV/PIV, EBV), precision immuno-oncology candidates (ER+ breast cancer, EGFRm+ NSCLC), and protein-replacement therapeutics (gout, cardiometabolic disease) primarily through enterprise partnerships with pharmaceutical and global health organizations.

Is Replicate Bioscience a public or private company?

Replicate Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Replicate Bioscience founded?

Replicate Bioscience was founded in 2014. It employs 11 to 50 people.

Where is Replicate Bioscience based?

Replicate Bioscience is headquartered in San Diego, United States, in the North America region.

How does Replicate Bioscience make money?

Four revenue lines are on record. Research funding and milestone payments are the primary driver. The others are royalty arrangements, grant funding and series A funding.

Who are Replicate Bioscience's main competitors?

Direct peers on record are Arcturus Therapeutics, Strand Therapeutics and Sail Biomedicines. Broad incumbents are Moderna, BioNTech, CureVac, Pfizer and Sanofi (Translate Bio). Emerging players are Vir Biotechnology and Tessera Therapeutics.

Does Replicate Bioscience have an API?

No public API is recorded for Replicate Bioscience.

What industry is Replicate Bioscience in?

Replicate Bioscience's product category is RNA Therapeutics and Vaccines. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SdbnReplicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis – San Diego Biotechnology NetworkReplicate Bioscience, a clinical-stage biotech company based in San Diego, has been awarded a grant from the Gates Foundation to advance its self-replicating RNA (srRNA) vaccine candidates for tuberculosis. The grant is subject to humanitarian licensing terms, indicating the research is intended for global health applications in underserved populations. This funding represents a strategic milestone for the company, enabling further development of its novel srRNA technology platform against a major infectious disease.AijournReplicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for TuberculosisReplicate Bioscience has been awarded approximately $3 million by the Gates Foundation to advance self-replicating RNA (srRNA) vaccine candidates for tuberculosis, marking the company's third grant from the foundation. The grant builds on Replicate's existing srRNA platform, which has demonstrated protective immune responses at low doses in Phase I trials for rabies. Replicate is also developing srRNA vaccines for HIV and malaria through additional Gates Foundation grants, and has partnered with Instituto Butantan for rabies vaccine commercialization in Latin America.PR NewswireReplicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for TuberculosisReplicate Bioscience has been awarded an approximately $3 million grant from the Gates Foundation to advance self-replicating RNA (srRNA) vaccine candidates for tuberculosis, marking the company's third grant from the foundation. The funding will support development of safe, effective, and globally accessible TB vaccines leveraging Replicate's clinically validated srRNA platform. Tuberculosis remains the leading infectious cause of death worldwide, responsible for more than one million deaths annually, with disproportionate impact on low- and middle-income countries.PR NewswireReplicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and MalariaReplicate Bioscience announced it has received two research grants totaling approximately $7 million from the Gates Foundation to develop self-replicating RNA (srRNA) vaccines for malaria and HIV. The first grant of ~$3.5 million will fund a low-dose, multigenic RNA-based malaria vaccine platform targeting low- and middle-income countries, while the second grant of equal value will support development of a novel HIV vaccine candidate. The company stated it will leverage its srRNA technology platform, which has demonstrated high therapeutic index in clinical trials, to advance these vaccine candidates under humanitarian licensing terms.ReplicatebioscienceReplicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and MalariaReplicate Bioscience received two Gates Foundation grants totaling about $7 million to develop an srRNA-based malaria vaccine and an HIV vaccine candidate. The grants aim to expand access to effective vaccines in low- and middle-income countries, with the company expecting improved durability and safety from its srRNA platform.SdbnReplicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria – San Diego Biotechnology NetworkReplicate Bioscience has been awarded approximately $7 million in funding from the Gates Foundation to develop new srRNA vaccines targeting HIV and malaria using the company's srRNA platform. The grants are subject to humanitarian licensing terms. The funding addresses two of the world's most persistent public health burdens.PR NewswireReplicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business OfficerReplicate Bioscience has appointed Kathy Fernando, Ph.D., as its new Chief Business Officer to lead corporate strategy and business development. This leadership change occurs as the clinical-stage company accelerates its pipeline of self-replicating RNA (srRNA) therapeutics for infectious diseases and immunology.PR NewswireReplicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin AmericaReplicate Bioscience and Instituto Butantan announced a collaboration agreement granting Instituto Butantan exclusive rights to develop and commercialize Replicate's srRNA rabies vaccine (RBI-4000) in Latin America. Under the terms, Instituto Butantan will fund registrational clinical trials and conduct manufacturing transfers, while Replicate retains development rights outside the region and is eligible for tiered royalties on future sales.BioXconomyNovo and Replicate join forces to combat obesity crisisClinical-stage firm Replicate Bioscience and pharmaceutical giant Novo Nordisk have entered a multi-year research collaboration to develop therapeutic approaches for cardiometabolic diseases using Replicate's self-replicating RNA technology. Under the agreement, Novo Nordisk will gain global license rights to the platform and could pay up to approximately $550 million in upfront and milestone payments plus royalties. This deal supports Novo Nordisk's ongoing strategy to expand its obesity treatment pipeline through strategic partnerships.ReutersNovo Nordisk seeks new obesity, diabetes drugs with Replicate BioScience partnershipNovo Nordisk will partner with Replicate Bioscience to develop RNA-based treatments for obesity, type 2 diabetes, and other cardiometabolic diseases. Novo will receive an exclusive worldwide license and provide up to $550 million in funding, including milestone payments and tiered royalties. Replicate's srRNA technology aims to trigger stronger immune responses with improved safety.